Efficacy and Safety of Long-Term Bulevirtide in Chronic Hepatitis Delta: Final Results From the Phase 3 MYR301 Study, Including 2 Participants With HIV/HBV/HDV Coinfection

Conference Reports for NATAP

Conference on Retroviruses
and Opportunistic Infections
Denver, CO 80202, United States
February 22 - 25, 2026


Efficacy and Safety of Long-Term Bulevirtide in Chronic Hepatitis Delta: Final Results From the Phase 3 MYR301 Study, Including 2 Participants With HIV/HBV/HDV Coinfection

	CROI 2026 Feb 22-25 Denver